VivoSeq
Oncology

Metastatic Lung Non-Small Cell Carcinoma

3

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Metastatic Lung Non-Small Cell Carcinoma is an early-stage landscape with 3 programs across 2 companies. The most active players are Eli Lilly, AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Necitumumab

Eli Lilly

Phase 22

Bevacizumab

Bio-Thera Solutions

Osimertinib

AstraZeneca

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Monoclonal antibody

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule133%

Monoclonal antibody leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

2

clinical trials

Active, not recruiting2 · 100%

Clinical Trials

Trial Activity

A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT02496663·138 enrolled
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02971501·5 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)